AP303 300 μg

DRUG2 trials

Sponsors

Alebund Pty Ltd, Alebund Pharmaceuticals

Conditions

Healthy Subjects

Phase 1

A Safety, Tolerability, and Pharmacokinetics Study of AP303 in Healthy Subjects

CompletedNCT05503693

Alebund Pty LtdHealthy Subjects

Start: 2022-12-06End: 2023-07-21Updated: 2024-05-30

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants

CompletedNCT06308523

Alebund PharmaceuticalsHealthy Subjects

Start: 2024-03-18End: 2024-05-13Updated: 2024-10-22